Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scancell Holdings PLC (GB:SCLP)
LSE:SCLP
RESEARCH TOOLSreports
Holding GB:SCLP?
Track your performance easily
SCLP Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range8.60p - 19.75p
Previous Close14.75p
Volume920.77K
Average Volume (3M)979.32K
Market Cap
£137.12M
Enterprise Value136.73M
Total Cash (Recent Filing)£19.92M
Total Debt (Recent Filing)£19.53M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Jan 30, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding927,819,977
10 Day Avg. Volume847,456
30 Day Avg. Volume979,318
Standard Deviation0.26
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)25.96
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scancell Holdings News
PremiumCompany Announcements
Scancell Holdings Moves Forward with Cancer Therapies
PremiumCompany Announcements
Scancell Holdings Announces Major Shareholding Changes
PremiumCompany Announcements
Scancell Holdings Welcomes New CEO Amid Strategic Shift
PremiumCompany Announcements
Scancell Holdings Strengthens Leadership with New CEO Appointment
PremiumCompany Announcements
Scancell Holdings Announces Upcoming AGMPremiumCompany Announcements
Scancell Holdings Reports Promising Vaccine Trials
PremiumCompany Announcements
Scancell Holdings Announces Upcoming Financial Results
PremiumCompany Announcements
Scancell Partners with PharmaJet for Melanoma Vaccine DeliveryOptions Prices
Currently, No data available
---
Ownership Overview
SCLP FAQ
What was Scancell Holdings PLC’s price range in the past 12 months?
Scancell Holdings PLC lowest share price was 8.60p and its highest was 19.75p in the past 12 months.
What is Scancell Holdings PLC’s market cap?
Currently, no data Available
When is Scancell Holdings PLC’s upcoming earnings report date?
Scancell Holdings PLC’s upcoming earnings report date is Jan 30, 2025 which is in 78 days.
How were Scancell Holdings PLC’s earnings last quarter?
Scancell Holdings PLC released its earnings results on Sep 24, 2024. The company reported -0.004p earnings per share for the quarter, missing the consensus estimate of N/A by -0.004p.
Is Scancell Holdings PLC overvalued?
According to Wall Street analysts Scancell Holdings PLC’s price is currently Overvalued.
Does Scancell Holdings PLC pay dividends?
Scancell Holdings PLC does not currently pay dividends.
What is Scancell Holdings PLC’s EPS estimate?
Scancell Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings PLC have?
Scancell Holdings PLC has 929,600,000 shares outstanding.
What happened to Scancell Holdings PLC’s price movement after its last earnings report?
Scancell Holdings PLC reported an EPS of -0.004p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Scancell Holdings PLC?
Currently, no hedge funds are holding shares in GB:SCLP
---
Scancell Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.11%
Trailing 12-Months
Company Description
Scancell Holdings PLC
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
---
SCLP Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---